Table 3 Platelet Function Profile of Patients with Major Depressive Disorder and Chronic Kidney Disease at Baseline and After 12 Weeks of Sertraline Treatment
|  | Sertraline, N = 88 | Placebo, N = 87 | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|
Platelet function | Baseline | Week 12 | Median change from baseline to week 12 | Baseline | Week 12 | Median change from baseline to week 12 | Between-groups at baselinea | Between groups at Week 12b | Between groups for changec |
A. Whole blood platelet aggregation induced by agonist (in ohms) | |||||||||
 0.5 mM arachidonic acid | 5 (0, 20) | 1 (0, 21) | −4.00 | 0 (0,10) | 0 (0, 10) | 0 | 0.08 | 0.04 | 0.14 |
 0.25 mM arachidonic acid | 0 (0, 17) | 0 (0, 15) | 0 | 0 (0, 14) | 0 (0, 6) | 0 | 0.40 | 0.22 | 0.07 |
 20 μM ADP | 10 (6, 14) | 8 (5, 12) | −2.00 | 11 (8, 14) | 11 (5, 15) | 0 | 0.82 | 0.22 | 0.10 |
 10 μM ADP | 10 (5, 12) | 10 (6, 14) | 0 | 10 (7, 15) | 10 (7, 15) | 0 | 0.08 | 0.15 | 0.23 |
 2 μg/mL collagen | 20 (14, 26) | 20 (15, 27) | 0 | 21 (14, 30) | 18 (13, 24) | −3.00 | 0.51 | 0.21 | 0.09 |
B. ATP secretion induced by agonist (in nmoles) | |||||||||
 0.5 mM arachidonic acid | 0.35 (0, 0.76) | 0.23 (0, 0.68) | −0.12 | 0.26 (0, 0.72) | 0.14 (0, 0.52) | −0.12 | 0.50 | 0.27 | 0.16 |
 0.25 mM arachidonic acid | 0.20 (0, 0.67) | 0.11 (0, 0.63) | −0.09 | 0.13 (0, 0.52) | 0 (0, 0.30) | −0.13 | 0.42 | 0.12 | 0.17 |
 2 μg/mL collagen | 0.71 (0.43, 1.11) | 0.62 (0.35, 0.88) | −0.09 | 0.52 (0.29, 0.91) | 0.55 (0.33, 0.89) | 0.03 | 0.05 | 0.74 | 0.13 |
 1 unit/mL thrombin | 1.17 (0.83, 1.73) | 0.87 (0.63, 1.15) | −0.30 | 1.02 (0.73, 1.43) | 0.90 (0.46, 1.37) | −0.12 | 0.09 | 0.71 | 0.39 |
C. Plasma levels of platelet activation markers (in pg/L) | |||||||||
 P-selectin | 34.10 (23.47, 49.24) | 32.99 (23.92, 42.73) | −1.11 | 36.36 (29.60, 41.20) | 31.32 (27.41, 43.13) | −5.04 | 0.90 | 0.57 | 0.44 |
 E-selectin | 42.06 (30.30, 59.95) | 40.35 (30.24, 60.30) | −1.71 | 43.53 (36.11, 51.33) | 44.38 (35.81, 56.05) | 0.85 | 0.97 | 0.41 | 0.34 |